will increase the level or effect of imipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely.indinavirfluvoxamine will increase the level or effect of indinavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.indomethacinfluvoxamine, indomethacin. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.irinotecanfluvoxamine will increase the level or effect of irinotecan by affecting hepatic enzyme CYP2B6 metabolism. Use Caution/Monitor.irinotecan liposomalfluvoxamine will increase the level or effect of irinotecan liposomal by affecting hepatic enzyme CYP2B6 metabolism. Use Caution/Monitor.isavuconazonium sulfatefluvoxamine will increase the level or effect of isavuconazonium sulfate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.isoniazidfluvoxamine and isoniazid both increase serotonin levels. Modify Therapy/Monitor Closely.itraconazoleitraconazole and fluvoxamine both increase QTc interval. Use Caution/Monitor.ivacaftorfluvoxamine will increase the level or effect of ivacaftor by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce ivacaftor dose if coadministered with CYP3A4 inhibitors; see ivacaftor prescribing information for precise dosage informationivosidenibfluvoxamine will increase the level or effect of ivosidenib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. May increase ivosidenib plasma concentrations, thus increasing risk of QTc prolongation; monitor for increased risk of QTc interval prolongationixabepilonefluvoxamine will increase the level or effect of ixabepilone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.ketaminefluvoxamine will increase the level or effect of ketamine by affecting hepatic enzyme CYP2B6 metabolism. Use Caution/Monitor.ketoconazolefluvoxamine and ketoconazole both increase QTc interval. Modify Therapy/Monitor Closely.ketoprofenfluvoxamine, ketoprofen. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding SSRIs inhib. serotonin uptake by platelets.ketorolacfluvoxamine, ketorolac. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding SSRIs inhib. serotonin uptake by platelets.ketorolac intranasalfluvoxamine, ketorolac intranasal. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding; SSRIs inhib. srotonin uptake by platelets.L-tryptophanfluvoxamine and L-tryptophan both increase serotonin levels. Modify Therapy/Monitor Closely.lamotriginelamotrigine increases toxicity of fluvoxamine by serotonin levels. Modify Therapy/Monitor Closely. psychomotor impairment may be enhanced.lansoprazolefluvoxamine will increase the level or effect of lansoprazole by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.lapatinibfluvoxamine and lapatinib both increase QTc interval. Use Caution/Monitor.lasmiditanfluvoxamine and lasmiditan both increase serotonin levels. Use Caution/Monitor.lefamulinfluvoxamine will increase the level or effect of lefamulin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Monitor for adverse effects if lefamulin is coadministered with moderate CYP3A inhibitors.lemborexantfluvoxamine will increase the level or effect of lemborexant by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Avoid coadministration of lemborexant with moderate or strong CYP3A4 inhibitorsfluvoxamine, lemborexant. Either increases effects of the other by sedation. Modify Therapy/Monitor Closely. May have additive effect with other CNS depressants; dose adjustment may be necessary.levamlodipinefluvoxamine will increase the level or effect of levamlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. May requre amlodipine dose reduction; monitor for symptoms of hypotension and edema when amlodipine is coadminitered with CYP3A4 inhibitors to determine need for those adjustmentlevofloxacinfluvoxamine and levofloxacin both increase QTc interval. Use Caution/Monitor.levoketoconazolefluvoxamine and levoketoconazole both increase QTc interval. Modify Therapy/Monitor Closely.lisdexamfetaminefluvoxamine, lisdexamfetamine. Either increases effects of the other by serotonin levels. Use Caution/Monitor. Initiate with lower doses and monitor for signs and symptoms of serotonin syndrome, particularly during initiation or dosage increase. If serotonin syndrome occurs, discontinue along with concomitant serotonergic drug(s).lithiumfluvoxamine and lithium both increase serotonin levels. Modify Therapy/Monitor Closely.lithium and fluvoxamine both increase QTc interval. Use Caution/Monitor.lofepraminefluvoxamine and lofepramine both increase QTc interval. Modify Therapy/Monitor Closely.lomitapidefluvoxamine will increase the level or effect of lomitapide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Lomitapide dose should not exceed 30 mg/daylonapegsomatropinlonapegsomatropin will decrease the level or effect of fluvoxamine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor. Limited published data indicate that growth hormone treatment increases cytochrome P450 (CYP450)-mediated antipyrine clearance. Caution with sensitive CYP substrateslopinavirfluvoxamine will increase the level or effect of lopinavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.loratadinefluvoxamine will increase the level or effect of loratadine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.lorcaserinlorcaserin will increase the level or effect of fluvoxamine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.lornoxicamfluvoxamine, lornoxicam. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.lsdfluvoxamine and lsd both increase serotonin levels. Modify Therapy/Monitor Closely.lumateperonefluvoxamine will increase the level or effect of lumateperone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce lumateperone dose to 21 mg/day if coadministered with moderate CYP3A4 inhibitors.lumefantrinefluvoxamine and lumefantrine both increase QTc interval. Modify Therapy/Monitor Closely.lurasidonefluvoxamine, lurasidone. Either increases toxicity of the other by sedation. Use Caution/Monitor. Monitor for increased adverse effects and toxicity.maprotilinefluvoxamine and maprotiline both increase QTc interval. Modify Therapy/Monitor Closely.maravirocfluvoxamine will increase the level or effect of maraviroc by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.mavacamtenfluvoxamine will increase the level or effect of mavacamten by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Inititiation of moderate CYP3A4 inhibitors may require decreased mavacamten dose. meclofenamatefluvoxamine, meclofenamate. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding SSRIs inhib. serotonin uptake by platelets.mefenamic acidfluvoxamine, mefenamic acid. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding SSRIs inhib. serotonin uptake by platelets.meloxicamfluvoxamine, meloxicam. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding; SSRIs inhib. srotonin uptake by platelets.metforminfluvoxamine increases effects of metformin by pharmacodynamic synergism. Use Caution/Monitor.methadonefluvoxamine and methadone both increase QTc interval. Use Caution/Monitor.methylphenidate transdermalmethylphenidate transdermal will increase the level or effect of fluvoxamine by decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. midazolamfluvoxamine will increase the level or effect of midazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. May increase risk of hypoventilation, airway obstruction, or apnea and may contribute to profound and/or prolonged drug effectmidazolam intranasalfluvoxamine will increase the level or effect of midazolam intranasal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. May increase risk of hypoventilation, airway obstruction, or apnea and may contribute to profound and/or prolonged drug effectmirabegronmirabegron will increase the level or effect of fluvoxamine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.mirtazapinefluvoxamine and mirtazapine both increase serotonin levels. Modify Therapy/Monitor Closely.morphinefluvoxamine and morphine both increase serotonin levels. Modify Therapy/Monitor Closely.moxifloxacinfluvoxamine and moxifloxacin both increase QTc interval. Modify Therapy/Monitor Closely.nabumetonefluvoxamine, nabumetone. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding SSRIs inhib. serotonin uptake by platelets.naldemedinefluvoxamine will increase the level or effect of naldemedine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Monitor for potential adverse effectsnaproxenfluvoxamine, naproxen. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.naratriptanfluvoxamine and naratriptan both increase serotonin levels. Modify Therapy/Monitor Closely.nateglinidefluvoxamine will increase the level or effect of nateglinide by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.nelfinavirfluvoxamine will increase the level or effect of nelfinavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.nicardipinefluvoxamine will increase the level or effect of nicardipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.nifedipinefluvoxamine will increase the level or effect of nifedipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.nilotinibfluvoxamine will increase the level or effect of nilotinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.nimodipinefluvoxamine will increase the level or effect of nimodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.nisoldipinefluvoxamine will increase the level or effect of nisoldipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.nitrendipinefluvoxamine will increase the level or effect of nitrendipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.norgestrelfluvoxamine will increase the level or effect of norgestrel by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Strong or moderate CYP3A4 inhibitors may increase systemic concentration of norgestrel, which may increase risk for adverse effects nortriptylinefluvoxamine and nortriptyline both increase QTc interval. Modify Therapy/Monitor Closely.octreotidefluvoxamine and octreotide both increase QTc interval. Modify Therapy/Monitor Closely.octreotide (Antidote)fluvoxamine and octreotide (Antidote) both increase QTc interval. Modify Therapy/Monitor Closely.ofloxacinfluvoxamine and ofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.oliceridinefluvoxamine will increase the level or effect of oliceridine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. If concomitant use is necessary, may require less frequent oliceridine dosing. Closely monitor for respiratory depression and sedation and titrate subsequent doses accordingly. If inhibitor is discontinued, consider increase oliceridine dosage until stable drug effects are achieved. Monitor for signs of opioid withdrawal. fluvoxamine, oliceridine. Either increases toxicity of the other by serotonin levels. Modify Therapy/Monitor Closely.ospemifenefluvoxamine will increase the level or effect of ospemifene by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.oxaprozinfluvoxamine, oxaprozin. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.oxycodonefluvoxamine and oxycodone both increase serotonin levels. Use Caution/Monitor.paliperidonefluvoxamine and paliperidone both increase QTc interval. Use Caution/Monitor.pantoprazolefluvoxamine will increase the level or effect of pantoprazole by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.parecoxibfluvoxamine will increase the level or effect of parecoxib by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Increased risk of upper GI bleeding; SSRIs inhib. srotonin uptake by plateletsparoxetinefluvoxamine and paroxetine both increase QTc interval. Use Caution/Monitor.peginterferon alfa 2bfluvoxamine, peginterferon alfa 2b. Other (see comment). Use Caution/Monitor. Comment: Therapeutic effect may be altered with coadministration of CYP2D6 substrates; peginterferon alpha-2b may increase or decrease levels of CYP2D6 substrate.pentazocinefluvoxamine and pentazocine both increase serotonin levels. Modify Therapy/Monitor Closely.pentoxifyllinefluvoxamine and pentoxifylline both increase anticoagulation. Use Caution/Monitor. may increase bleedingperphenazinefluvoxamine and perphenazine both increase QTc interval. Use Caution/Monitor.phenytoinfluvoxamine will increase the level or effect of phenytoin by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.piroxicamfluvoxamine, piroxicam. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.posaconazolefluvoxamine and posaconazole both increase QTc interval. Use Caution/Monitor.pregabalinfluvoxamine, pregabalin. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration may result in life-threatening, and fatal respiratory depression; use lowest dose possible and monitor for respiratory depression and sedation.primaquineprimaquine and fluvoxamine both increase QTc interval. Use Caution/Monitor.prochlorperazinefluvoxamine and prochlorperazine both increase QTc interval. Use Caution/Monitor.promazinefluvoxamine and promazine both increase QTc interval. Modify Therapy/Monitor Closely.promethazinefluvoxamine and promethazine both increase QTc interval. Use Caution/Monitor.propafenonefluvoxamine will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.propofolfluvoxamine will increase the level or effect of propofol by affecting hepatic enzyme CYP2B6 metabolism. Use Caution/Monitor.protriptylinefluvoxamine and protriptyline both increase QTc interval. Modify Therapy/Monitor Closely.quetiapinefluvoxamine will increase the level or effect of quetiapine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.quinidinequinidine will increase the level or effect of fluvoxamine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.rabeprazolefluvoxamine will increase the level or effect of rabeprazole by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.ramelteonfluvoxamine will increase the level or effect of ramelteon by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.ranolazinefluvoxamine and ranolazine both increase QTc interval. Use Caution/Monitor.remimazolamremimazolam, fluvoxamine. Either increases toxicity of the other by sedation. Modify Therapy/Monitor Closely. Coadministration may result in profound sedation, respiratory depression, coma, and/or death. Continuously monitor vital signs during sedation and recovery period if coadministered. Carefully titrate remimazolam dose if administered with opioid analgesics and/or sedative/hypnotics.repaglinidefluvoxamine will increase the level or effect of repaglinide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.riluzolefluvoxamine will increase the level or effect of riluzole by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.rimegepantfluvoxamine will increase the level or effect of rimegepant by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Avoid repeating dose within 48 hr if coadministered with moderate CYP3A4risperidonefluvoxamine and risperidone both increase QTc interval. Use Caution/Monitor.ritlecitinibritlecitinib will increase the level or effect of fluvoxamine by affecting hepatic enzyme CYP1A2 metabolism. Modify Therapy/Monitor Closely. Ritlecitinib inhibits CYP1A2 substrates; coadministration increases AUC and peak plasma concentration sensitive substrates, which may increase risk of adverse reactions. Additional monitoring and dosage adjustment may be needed in accordance with product labeling of CYP1A2 substrates. ritonavirfluvoxamine will increase the level or effect of ritonavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.rivaroxabanfluvoxamine will increase the level or effect of rivaroxaban by pharmacodynamic synergism. Use Caution/Monitor. May increase risk of bleedingrizatriptanfluvoxamine and rizatriptan both increase serotonin levels. Modify Therapy/Monitor Closely.roflumilastfluvoxamine increases levels of roflumilast by Other (see comment). Modify Therapy/Monitor Closely. Comment: coadministration with dual inhibitors of CYP3A4 and CYP1A2 may increase systemic exposure and result in increased adverse reactions.rolapitantrolapitant will increase